{"id":131817,"date":"2022-07-29T08:08:58","date_gmt":"2022-07-29T12:08:58","guid":{"rendered":"https:\/\/44.250.171.167\/?p=131817"},"modified":"2022-10-06T04:29:08","modified_gmt":"2022-10-06T08:29:08","slug":"laurus-labs-limited-q1-fy23-earnings-conference-call-insights","status":"publish","type":"post","link":"https:\/\/alphastreet.com\/india\/laurus-labs-limited-q1-fy23-earnings-conference-call-insights\/","title":{"rendered":"Laurus Labs Limited Q1 FY23 Earnings Conference Call Insights"},"content":{"rendered":"<p><iframe loading=\"lazy\" title=\"Laurus Labs Limited Q1 FY23 Earnings Concall\" width=\"500\" height=\"375\" src=\"https:\/\/www.youtube.com\/embed\/gMXrmnAGz9Y?feature=oembed\" frameborder=\"0\" allow=\"accelerometer; autoplay; clipboard-write; encrypted-media; gyroscope; picture-in-picture; web-share\" referrerpolicy=\"strict-origin-when-cross-origin\" allowfullscreen><\/iframe><\/p>\n<p><strong>Key highlights from Laurus Labs Limited (<a href=\"https:\/\/44.250.171.167\/symbol\/LAURUSLABS\/\">LAURUSLABS<\/a>) Q1 FY23 Earnings Concall<\/strong><\/p>\n<p><strong>Management Update:<\/strong><\/p>\n<ul>\n<li>LAURUSLABS said it expects the US filing pace to pick up in FY23. In new markets, the company validated two products as part of CMO opportunity and expects significant upside in FY23 from these products.<\/li>\n<\/ul>\n<p><strong>Q&amp;A Highlights:<\/strong><\/p>\n<ul>\n<li>Sudarshan Padmanabhan from JM Financial asked that on the formulation side, if the company is seeing the run rate moving ahead and when the capacity will be optimally utilized. Satyanarayana Chava CEO said that capacity is fully qualified now but will be fully utilized by end of CY22.<\/li>\n<\/ul>\n<ul>\n<li>Krish Mehta of Enam Holdings enquired about the breakup of ARV versus non-ARV sales for 1Q23. Satyanarayana Chava CEO replied that ARV APIs is at 25% of company sales and 17% of sales came from the ARV formulations. Summing it up, 42% of sales came from ARVs, API and formulations together.<\/li>\n<\/ul>\n<ul>\n<li>Amey Chalke with Haitong Securities asked that margin improvement in synthesis business has been minimal. Satyanarayana Chava CEO replied that there was price pressure on ARVs. The reduction in ARVs was offset by higher margin in CDMO business.<\/li>\n<\/ul>\n<ul>\n<li>Amey Chalke of Haitong Securities also asked about the higher other expense in 1Q23 vs. 4Q22. Ravi Kumar CFO said that on the expenses side, there is a power shortage in the company\u2019s manufacturing area in Andhra. LAURUSLABS spent around INR33 crores additional expenses towards power. And some forex de-stated loss is also reflected in the other expense.<\/li>\n<\/ul>\n<ul>\n<li>Amey Chalke of Haitong Securities also asked if the company expects the other expense to normalize in the near term. Ravi Kumar CFO answered that the company expects the expense to normalize. This is in light of the power and fuel getting normalized already.<\/li>\n<\/ul>\n<ul>\n<li>Amey Chalke of Haitong Securities asked that if GM remains at similar level, does EBITDA margin have scope to improve. Ravi Kumar CFO replied that the company is reiterating the EBITDA margin guidance for FY23 of around 30%.<\/li>\n<\/ul>\n<ul>\n<li>Nikhil Mathur from HDFC Mutual Fund asked about the capex dedicated for the custom synthesis business in the INR2,000 crore. \u00a0Satyanarayana Chava CEO clarified the INR2,000 crore is for FY23-24. The company said 40-50% of the capex is in the CDMO space. The remaining INR1,000 crores is going into non-ARV API and formulations or backward integrations.<\/li>\n<\/ul>\n<ul>\n<li>Nikhil Mathur with HDFC Mutual Fund enquired about the revenue outlook for Laurus Bio for the next 2-3 years. Satyanarayana Chava CEO said the company did INR30 crore sales in 1Q23 and 2Q will be similar. In 3Q and 4Q, the company expects debottlenecking of downstream processing, which should increase revenues. For FY24, it should be flat for Bio.<\/li>\n<\/ul>\n<ul>\n<li>Tushar Manudhane of Motilal Oswal asked about the incremental operational cost associated with the new brownfield capacity. Satyanarayana Chava CEO replied that the company\u2019s formulations expansion capacity is fully manned. Therefore, those expense are always built in in 1Q itself. If there is slight increase, it will be built in, in 2Q.<\/li>\n<\/ul>\n","protected":false},"excerpt":{"rendered":"<p>Key highlights from Laurus Labs Limited (LAURUSLABS) Q1 FY23 Earnings Concall Management Update: LAURUSLABS said it expects the US filing pace to pick up in FY23. In new markets, the company validated two products as part of CMO opportunity and expects significant upside in FY23 from these products. Q&amp;A Highlights: Sudarshan Padmanabhan from JM Financial [&hellip;]<\/p>\n","protected":false},"author":1767,"featured_media":125416,"comment_status":"open","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"jetpack_post_was_ever_published":false,"footnotes":"","jetpack_publicize_message":"Laurus Labs Limited Q1 FY23 Earnings Conference Call Insights #LAURUSLABS #Q1 #FY23","jetpack_publicize_feature_enabled":true,"jetpack_social_post_already_shared":true,"jetpack_social_options":{"image_generator_settings":{"template":"highway","default_image_id":0,"font":"","enabled":false},"version":2}},"categories":[9825,392,5747],"tags":[898,3187],"class_list":["post-131817","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-earnings-call-highlights","category-earnings","category-healthcare-stocks","tag-biotech","tag-biotechnology"],"jetpack_publicize_connections":[],"jetpack_featured_media_url":"https:\/\/alphastreet.com\/india\/wp-content\/uploads\/2021\/11\/Earnings-Coverage.jpg","jetpack_likes_enabled":false,"jetpack-related-posts":[{"id":128735,"url":"https:\/\/alphastreet.com\/india\/laurus-labs-limited-q4-fy22-earnings-conference-call-insights\/","url_meta":{"origin":131817,"position":0},"title":"Laurus Labs Limited Q4 FY22 Earnings Conference Call Insights","author":"Praveen","date":"May 2, 2022","format":false,"excerpt":"https:\/\/youtu.be\/83rl6ffkU9c Key highlights from Laurus Labs Limited (LAURUSLABS) Q4 FY22 Earnings Concall Management Update: LAURUSLABS said that based on its healthy product pipeline, it continues to invest in FDF infrastructure. And brownfield expansion at Unit 2 is progressing as per expectation and is expected to add significant capacity to FDF\u2026","rel":"","context":"In &quot;Concall Highlights&quot;","block_context":{"text":"Concall Highlights","link":"https:\/\/alphastreet.com\/india\/category\/earnings-call-highlights\/"},"img":{"alt_text":"","src":"https:\/\/i0.wp.com\/alphastreet.com\/india\/wp-content\/uploads\/2021\/11\/Earnings-Coverage.jpg?resize=350%2C200&ssl=1","width":350,"height":200,"srcset":"https:\/\/i0.wp.com\/alphastreet.com\/india\/wp-content\/uploads\/2021\/11\/Earnings-Coverage.jpg?resize=350%2C200&ssl=1 1x, https:\/\/i0.wp.com\/alphastreet.com\/india\/wp-content\/uploads\/2021\/11\/Earnings-Coverage.jpg?resize=525%2C300&ssl=1 1.5x"},"classes":[]},{"id":135224,"url":"https:\/\/alphastreet.com\/india\/laurus-labs-limited-q2-fy23-earnings-conference-call-insights\/","url_meta":{"origin":131817,"position":1},"title":"Laurus Labs Limited Q2 FY23 Earnings Conference Call Insights","author":"Praveen","date":"October 27, 2022","format":false,"excerpt":"https:\/\/youtu.be\/ZaM0EH45MvA Key highlights from Laurus Labs Limited (LAURUSLABS) Q2 FY23 Earnings Concall Management Update: [00:10:45] LAURUSLABS said that on the R&D front, it\u2019s continuing to allocate critical resources to its initiatives and invest in portfolio with product-specific approach based on complexity and scale of economies. The company added that it\u2019s\u2026","rel":"","context":"In &quot;Concall Highlights&quot;","block_context":{"text":"Concall Highlights","link":"https:\/\/alphastreet.com\/india\/category\/earnings-call-highlights\/"},"img":{"alt_text":"","src":"https:\/\/i0.wp.com\/alphastreet.com\/india\/wp-content\/uploads\/2021\/11\/Earnings-Coverage.jpg?resize=350%2C200&ssl=1","width":350,"height":200,"srcset":"https:\/\/i0.wp.com\/alphastreet.com\/india\/wp-content\/uploads\/2021\/11\/Earnings-Coverage.jpg?resize=350%2C200&ssl=1 1x, https:\/\/i0.wp.com\/alphastreet.com\/india\/wp-content\/uploads\/2021\/11\/Earnings-Coverage.jpg?resize=525%2C300&ssl=1 1.5x"},"classes":[]},{"id":139585,"url":"https:\/\/alphastreet.com\/india\/laurus-labs-limited-q3-fy23-earnings-conference-call-insights\/","url_meta":{"origin":131817,"position":2},"title":"Laurus Labs Limited Q3 FY23 Earnings Conference Call Insights","author":"Praveen","date":"January 31, 2023","format":false,"excerpt":"Key highlights from Laurus Labs Limited (LAURUSLABS) Q3 FY23 Earnings Concall Management Update: [00:03:57] LAURUSLABS said its strong results were driven by growth in non-ARV revenues, especially CDMO and API, and recovery in ARV formulations that is expected to continue further. Q&A Highlights: [00:18:37] Sajal Kapoor asked about the anticipated\u2026","rel":"","context":"In &quot;Concall Highlights&quot;","block_context":{"text":"Concall Highlights","link":"https:\/\/alphastreet.com\/india\/category\/earnings-call-highlights\/"},"img":{"alt_text":"","src":"https:\/\/i0.wp.com\/alphastreet.com\/india\/wp-content\/uploads\/2021\/11\/Earnings-Coverage.jpg?resize=350%2C200&ssl=1","width":350,"height":200,"srcset":"https:\/\/i0.wp.com\/alphastreet.com\/india\/wp-content\/uploads\/2021\/11\/Earnings-Coverage.jpg?resize=350%2C200&ssl=1 1x, https:\/\/i0.wp.com\/alphastreet.com\/india\/wp-content\/uploads\/2021\/11\/Earnings-Coverage.jpg?resize=525%2C300&ssl=1 1.5x"},"classes":[]},{"id":144523,"url":"https:\/\/alphastreet.com\/india\/laurus-labs-limited-q4-fy23-earnings-conference-call-insights\/","url_meta":{"origin":131817,"position":3},"title":"Laurus Labs Limited Q4 FY23 Earnings Conference Call Insights","author":"Praveen","date":"April 28, 2023","format":false,"excerpt":"https:\/\/youtu.be\/5Vtl-XMN8qg Key highlights from Laurus Labs Limited (LAURUSLABS) Q4 FY23 Earnings Concall Management Update: [00:09:24]LAURUSLABS said it invested in expanding non-ARV formulation infrastructure with a capacity of 10 billion units. The company expects brownfield capacities added in FY23 to be better utilized in FY24 due to better demand visibility in\u2026","rel":"","context":"In &quot;Concall Highlights&quot;","block_context":{"text":"Concall Highlights","link":"https:\/\/alphastreet.com\/india\/category\/earnings-call-highlights\/"},"img":{"alt_text":"","src":"https:\/\/i0.wp.com\/alphastreet.com\/india\/wp-content\/uploads\/2021\/11\/Earnings-Coverage.jpg?resize=350%2C200&ssl=1","width":350,"height":200,"srcset":"https:\/\/i0.wp.com\/alphastreet.com\/india\/wp-content\/uploads\/2021\/11\/Earnings-Coverage.jpg?resize=350%2C200&ssl=1 1x, https:\/\/i0.wp.com\/alphastreet.com\/india\/wp-content\/uploads\/2021\/11\/Earnings-Coverage.jpg?resize=525%2C300&ssl=1 1.5x"},"classes":[]},{"id":126876,"url":"https:\/\/alphastreet.com\/india\/laurus-labs-limited-q3-fy22-earnings-conference-call-insights\/","url_meta":{"origin":131817,"position":4},"title":"Laurus Labs Limited Q3 FY22 Earnings Conference Call Insights","author":"Praveen","date":"January 31, 2022","format":false,"excerpt":"https:\/\/www.youtube.com\/watch?v=Q_K9qU7RXvI Key highlights from Laurus Labs Limited (LAURUSLABS) Q3 FY22 Earnings Concall Management Update: In 3Q, the company faced some interim challenges due to logistics, raw material availability and higher prices, especially for solvents as like the industry. Though the company is seeing these challenges easing out, supply chain and\u2026","rel":"","context":"In &quot;Concall Highlights&quot;","block_context":{"text":"Concall Highlights","link":"https:\/\/alphastreet.com\/india\/category\/earnings-call-highlights\/"},"img":{"alt_text":"","src":"https:\/\/i0.wp.com\/alphastreet.com\/india\/wp-content\/uploads\/2021\/11\/Earnings-Coverage.jpg?resize=350%2C200&ssl=1","width":350,"height":200,"srcset":"https:\/\/i0.wp.com\/alphastreet.com\/india\/wp-content\/uploads\/2021\/11\/Earnings-Coverage.jpg?resize=350%2C200&ssl=1 1x, https:\/\/i0.wp.com\/alphastreet.com\/india\/wp-content\/uploads\/2021\/11\/Earnings-Coverage.jpg?resize=525%2C300&ssl=1 1.5x"},"classes":[]},{"id":143078,"url":"https:\/\/alphastreet.com\/india\/laurus-labs-q3fy23-net-profit-rises-by-32-percent\/","url_meta":{"origin":131817,"position":5},"title":"Laurus Labs Q3FY23 net profit rises by 32 percent","author":"Chirag Gupta","date":"March 1, 2023","format":false,"excerpt":"Pharmaceutical and biotechnology company Laurus Labs reported 32% year-on-year (YoY) rise in profit after tax to INR 203 crore for the quarter ended December 31, 2022. The company had reported a net profit of INR 155 crore in the same quarter, previous fiscal year. The company's consolidated revenue from operations\u2026","rel":"","context":"In &quot;Earnings&quot;","block_context":{"text":"Earnings","link":"https:\/\/alphastreet.com\/india\/category\/earnings\/"},"img":{"alt_text":"earnings preview","src":"https:\/\/i0.wp.com\/alphastreet.com\/india\/wp-content\/uploads\/2019\/04\/Earnings-preview-1.jpg?resize=350%2C200&ssl=1","width":350,"height":200,"srcset":"https:\/\/i0.wp.com\/alphastreet.com\/india\/wp-content\/uploads\/2019\/04\/Earnings-preview-1.jpg?resize=350%2C200&ssl=1 1x, https:\/\/i0.wp.com\/alphastreet.com\/india\/wp-content\/uploads\/2019\/04\/Earnings-preview-1.jpg?resize=525%2C300&ssl=1 1.5x, https:\/\/i0.wp.com\/alphastreet.com\/india\/wp-content\/uploads\/2019\/04\/Earnings-preview-1.jpg?resize=700%2C400&ssl=1 2x, https:\/\/i0.wp.com\/alphastreet.com\/india\/wp-content\/uploads\/2019\/04\/Earnings-preview-1.jpg?resize=1050%2C600&ssl=1 3x"},"classes":[]}],"jetpack_sharing_enabled":true,"_links":{"self":[{"href":"https:\/\/alphastreet.com\/india\/wp-json\/wp\/v2\/posts\/131817","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/alphastreet.com\/india\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/alphastreet.com\/india\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/alphastreet.com\/india\/wp-json\/wp\/v2\/users\/1767"}],"replies":[{"embeddable":true,"href":"https:\/\/alphastreet.com\/india\/wp-json\/wp\/v2\/comments?post=131817"}],"version-history":[{"count":0,"href":"https:\/\/alphastreet.com\/india\/wp-json\/wp\/v2\/posts\/131817\/revisions"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/alphastreet.com\/india\/wp-json\/wp\/v2\/media\/125416"}],"wp:attachment":[{"href":"https:\/\/alphastreet.com\/india\/wp-json\/wp\/v2\/media?parent=131817"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/alphastreet.com\/india\/wp-json\/wp\/v2\/categories?post=131817"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/alphastreet.com\/india\/wp-json\/wp\/v2\/tags?post=131817"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}